SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Coronary artery disease (CAD); type 2 diabetes	Cyclin dependent kinase inhibitor 2B (CDKN2B; INK4B; MTS2); interferon-α_{21} (IFNA21); methylthioadenosine phosphorylase (MTAP)	*In vitro* studies suggest that targeting CDKN2B, IFNA21 and MTAP could be useful for treating CAD or type 2 diabetes associated with inflammation. DNA sequencing, binding studies and cell culture identified 9p21 locus mutations that altered expression of *CDKN2B*, *IFNA21* and *MTAP* in response to proinflammatory signaling. Next steps include cell culture and animal studies of how genes regulated by the 9p21 risk locus affect inflammatory responses in coronary artery tissue. *SciBX* 4(9); doi:10.1038/scibx.2011.261 Published online March 3, 2011	Unpatented; licensing status not applicable	Harismendy, O. *et al. Nature*; published online Feb. 10, 2011; doi:10.1038/nature09753 **Contact:** Kelly A. Frazer, University of California, San Diego, La Jolla, Calif. e-mail: kafrazer@ucsd.edu